Feb 25 InterMune Inc said its
experimental lung drug reduced the progression of a disease that
leads to loss of lung function in a late-stage trial.
The trial compared the drug, pirfenidone, with a placebo,
and showed that after 52 weeks of treatment, 16.5 percent of
patients in the pirfenidone group experienced disease
progression, compared with 31.8 percent in the placebo group.
The disease, idiopathic pulmonary fibrosis (IPF), is an
irreversible condition that leads to progressive loss of lung
function due to scarring, which hinders the lungs' ability to
InterMune said it expected to submit a marketing application
for the drug to the U.S. Food and Drug Administration by early
third quarter of this year.
Trading in the company's shares was halted ahead of the
announcement. They closed at $13.96 on the Nasdaq on Monday.